Vanda Pharmaceuticals (VNDA) detailed its expanding therapeutic portfolio and operational growth at the September 15, 2026, H.C. Wainwright Global Investment Conference, underscoring its strategic expansion in psychiatry and dermatology. The company reported five approved U.S. products—four already launched—with additional candidates advancing through clinical trials, including potential approvals by year-end 2026.
The company’s sales force has nearly tripled since 2024, growing from 50 representatives to 300, reflecting its intensified focus on psychiatry. Fanapt, its flagship atypical antipsychotic approved for schizophrenia and bipolar disorder, remains a cornerstone, generating over $100 million annually with a 30% year-over-year revenue increase. However, its gross-to-net margin of around 50% contrasts sharply with BYSANTI, its bioequivalent version, which is expected to launch by year-end 2026 with a Medicaid discount of 23.1% and a gross-to-net profile in the mid-30% range.
Vanda’s dermatology portfolio includes imsidolimab (Qulmilza), a licensed treatment for generalized pustular psoriasis (GPP), with a December 2026 PDUFA date. The company also highlighted HETLIOZ, approved for sleep-wake disorders, and NEREUS, approved for motion sickness but being evaluated for nausea and vomiting linked to GLP-1 drugs like Wegovy. Phase III readouts for HETLIOZ in delayed sleep phase disorder and VQW-765 in social performance anxiety are expected by the end of 2026.
Operational efficiency remains a focus, with Q2 2026 marking the peak for operating expenses, which are projected to stabilize through Q3 before easing into 2027. Despite a $143 million negative leveraged free cash flow over the past year, Vanda’s cash position declined from $260 million in 2026 to $170 million by Q2, reflecting ongoing investment in pipeline development.
The company’s market positioning is bolstered by large patient populations: approximately 3 million Americans live with schizophrenia, while bipolar disorder affects about 2 to 3 times that number. Motion sickness impacts over 70 million, with 10 million seeking treatment annually, while GPP affects between 5,000 and 30,000 patients. BYSANTI’s potential expansion into major depressive disorder (MDD) is also underway, with Phase III readouts expected in the first half of 2027, potentially supporting an sNDA submission and label expansion by 2028.
Fanapt’s exclusivity is set to expire toward the end of 2027, a timeline that could pressure margins for its successor products. Vanda’s broader strategy hinges on diversifying revenue streams across psychiatry and dermatology, with upcoming catalysts including BYSANTI’s launch, imsidolimab’s potential approval, and clinical data for emerging candidates.
The company’s financials highlight a balanced approach between growth investments and cost management, positioning Vanda as a mid-sized biopharma with a pipeline that could sustain expansion beyond its core indications.
